Adolescents and young adults with Type 1 diabetes benefit from participation in a standard DTTP for flexible, intensive insulin therapy and dietary freedom.
Aims: The retina is protected against high blood pressure by the myogenic constriction of arterioles (the Bayliss effect). Hyperglycemia impairs this retinal autoregulation by endothelial dysfunction. The purpose of this prospective pilot study was to test whether improved metabolic control results in a measurable effect on the myogenic response of human retinal arterioles to acute increases in blood pressure. Methods: The Bayliss effect was measured in 25 patients with diabetes mellitus by the Retinal Vessel Analyzer (RVA), both before and after participation in a treatment and teaching program for intensified insulin therapy with the goal of improved metabolic control. After 12 months, 17 subjects still fulfilled the inclusion criteria and underwent an identical measurement. The Wilcoxon test was used for statistical analysis. Results: During the first session, a rise in mean arterial pressure (MAP) of 20.2 ± 8.6 mm Hg was followed by an arterial vasoconstriction of –3.2 ± 2.9%. The educational program resulted in a significant drop in HbA1c levels (9.4 ± 1.9 vs. 6.9 ± 0.98%). Eight subjects did not meet the inclusion criteria after 12 months. Seventeen subjects were remeasured and a rise in blood pressure of 19.5 ± 9.9 mm Hg in the second session was associated with a significantly improved arterial vasoconstriction of –5.9 ± 2.7% (session I vs. session II, p = 0.006). Conclusion: The myogenic response of the arterial wall in human retinal arterioles was significantly improved by the therapeutic intervention.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.